JP2006503597A5 - - Google Patents

Info

Publication number

JP2006503597A5

JP2006503597A5 JP2003559582A JP2003559582A JP2006503597A5 JP 2006503597 A5 JP2006503597 A5 JP 2006503597A5 JP 2003559582 A JP2003559582 A JP 2003559582A JP 2003559582 A JP2003559582 A JP 2003559582A JP 2006503597 A5 JP2006503597 A5 JP 2006503597A5

Authority

JP

Japan

Prior art keywords

patient

medical

drug delivery

delivery system

controller

Prior art date

2002-12-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000001802 infusion Methods 0.000 claims description 156
• 238000000034 method Methods 0.000 claims description 56
• 239000003814 drug Substances 0.000 claims description 30
• 229940079593 drug Drugs 0.000 claims description 28
• 239000007788 liquid Substances 0.000 claims description 28
• 238000011282 treatment Methods 0.000 claims description 28
• 238000012377 drug delivery Methods 0.000 claims description 25
• 230000000007 visual effect Effects 0.000 claims description 16
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
• 238000005086 pumping Methods 0.000 claims description 10
• 230000007246 mechanism Effects 0.000 claims description 9
• 230000008569 process Effects 0.000 claims description 6
• 238000012545 processing Methods 0.000 claims description 6
• 102000004877 Insulin Human genes 0.000 claims description 5
• 108090001061 Insulin Proteins 0.000 claims description 5
• 230000019522 cellular metabolic process Effects 0.000 claims description 5
• 229940125396 insulin Drugs 0.000 claims description 5
• 230000002503 metabolic effect Effects 0.000 claims description 5
• 230000003444 anaesthetic effect Effects 0.000 claims description 4
• 239000000599 controlled substance Substances 0.000 claims 12
• 239000008280 blood Substances 0.000 claims 1
• 210000004369 blood Anatomy 0.000 claims 1
• 238000002347 injection Methods 0.000 claims 1
• 239000007924 injection Substances 0.000 claims 1
• 230000003287 optical effect Effects 0.000 claims 1
• 230000005540 biological transmission Effects 0.000 description 19
• 238000010586 diagram Methods 0.000 description 14
• 238000007726 management method Methods 0.000 description 11
• 230000004044 response Effects 0.000 description 9
• 238000004891 communication Methods 0.000 description 8
• 230000033764 rhythmic process Effects 0.000 description 8
• 230000036541 health Effects 0.000 description 7
• 238000002560 therapeutic procedure Methods 0.000 description 7
• 230000000694 effects Effects 0.000 description 6
• 238000012544 monitoring process Methods 0.000 description 6
• 230000008859 change Effects 0.000 description 5
• 206010028980 Neoplasm Diseases 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 230000033001 locomotion Effects 0.000 description 4
• 230000007257 malfunction Effects 0.000 description 4
• 230000000284 resting effect Effects 0.000 description 4
• 230000035945 sensitivity Effects 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 3
• 229940041181 antineoplastic drug Drugs 0.000 description 3
• 230000036772 blood pressure Effects 0.000 description 3
• 230000036760 body temperature Effects 0.000 description 3
• 230000007613 environmental effect Effects 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 210000004377 supraoptic nucleus Anatomy 0.000 description 3
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 238000002651 drug therapy Methods 0.000 description 2
• 229960001904 epirubicin Drugs 0.000 description 2
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
• 229960000961 floxuridine Drugs 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 230000004066 metabolic change Effects 0.000 description 2
• 230000000737 periodic effect Effects 0.000 description 2
• 230000004962 physiological condition Effects 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 206010052804 Drug tolerance Diseases 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• 239000003994 anesthetic gas Substances 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 210000004027 cell Anatomy 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 230000002778 chronopharmacological effect Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 229960003624 creatine Drugs 0.000 description 1
• 239000006046 creatine Substances 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 238000013500 data storage Methods 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000036267 drug metabolism Effects 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000012631 food intake Nutrition 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
• 229960003987 melatonin Drugs 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012806 monitoring device Methods 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 238000011458 pharmacological treatment Methods 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 210000004560 pineal gland Anatomy 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1